

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-03-12 to 2026-04-11 (30 days)

Generated: 2026-04-11 09:03:19

Executive Summary


Sentiment analysis for Illumina (ILMN) from 2026-03-12 to 2026-04-11. Analyzed 151 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	40	26.5%
Negative	57	37.7%
Neutral	54	35.8%
Total	151	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
The weak point: Why pharmaceutical security belong...	news	2026-04-10	0.900
Evolution of a truncated nucleocapsid protein enha...	news	2026-04-01	0.869
Molecular Tumor Board Solutions Market Outlook 202...	news	2026-04-07	0.832
I'm a wellness writer — 40 of my favorite products...	news	2026-03-25	0.805
Artificial Intelligence in Oncology: Assessment of...	news	2026-03-30	0.799

Top Negative Events

Title	Source	Date	Score
Single-cell transcriptome profiling reveals herpes...	news	2026-04-02	-1.000
DNMT1 loss leads to hypermethylation of a subset o...	news	2026-04-02	-0.984
I tried the next frontier in cancer screening. I'm...	news	2026-04-09	-0.906
Biobanking of gynecologic cancer biospecimens: Dev...	news	2026-03-31	-0.869
New phs004508.v1.p1 Dendritic Cell Redundancy ...	news	2026-03-27	-0.869